Altogether, RIPK1 inhibitors (Riebeling et al., 2021) may offer a potential treatment for young COVID‐19 patients, such as COVID‐19‐related multisystem inflammatory syndrome in children (MIS‐C) (Rowley, 2020). This evidence concerns the gene RIPK1 and COVID-19.